IDEAYA Biosciences, Inc.
IDYA
Ранг среди акций
#4748
IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to... IDEAYA Biosciences, Inc. is a precision oncology company primarily dedicated to identifying and advancing targeted therapies, particularly leveraging the concept of synthetic lethality. The firm aims to develop specific treatments for patient groups selected through molecular diagnostic methods. At the forefront of its clinical efforts are two investigational drugs. IDE397, a methionine adenosyltransferase 2a (MAT2A) blocking agent, is currently in early-stage (Phase I) trials for solid tumors exhibiting methylthioadenosine phosphorylase (MTAP) deletions. Its second primary candidate, IDE196, a protein kinase C (PKC) inhibitor, is progressing through Phase I/II studies, targeting genetically defined cancers characterized by GNAQ or GNA11 gene mutations. Beyond its clinical pipeline, IDEAYA's earlier-stage portfolio includes several synthetic lethality programs. These encompass a PARG inhibitor designed to address tumors with specific genetic or molecular biomarkers, Pol Theta inhibitors aimed at cancers presenting with BRCA or other homologous recombination deficiency (HRD) mutations, and WRN inhibitors for tumors demonstrating high microsatellite instability (MSI-H). The company also engages in significant collaborations. It has a joint research effort with Cancer Research UK and the University of Manchester, focusing on small molecule inhibitors of Poly (ADP-ribose) glycohydrolase. Furthermore, IDEAYA maintains a partnership with Pfizer Inc. for the clinical development and supply in Phase I/II trials across metastatic uveal melanoma, skin melanoma, and other solid tumors, alongside a strategic alliance with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was established in 2015 and operates from its headquarters in South San Francisco, California.
Цена акции
$32.83
Последняя синхронизация: 2026-10-16
Рыночная капитализация
$3.17B
Изменение (1 день)
-3.01%
Изменение (1 год)
12.20%
Страна
US
Торговля IDEAYA Biosciences, Inc. (IDYA)
Категория
Healthcare
Операционная маржа для IDEAYA Biosciences, Inc. (IDYA)
Операционная маржа на October 2026 TTM: -92.66%
Согласно последним финансовым отчетам и цене акций IDEAYA Biosciences, Inc., текущая операционная маржа (TTM) составляет -92.66%. В конце 2023 она составила -574.85%.
История операционной маржи IDEAYA Biosciences, Inc. с 2017 по 2026
Операционная маржа на конец каждого года
| Год | Операционная маржа | Изменить |
|---|---|---|
| 2026 (TTM) | -92.66% | -98.02% |
| 2024 | -4,671.07% | 712.57% |
| 2023 | -574.85% | 368.42% |
| 2022 | -122.72% | -31.79% |
| 2021 | -179.91% | -0.55% |
| 2020 | -180.90% | 0.00% |
| 2019 | 0.00% | 0.00% |
| 2018 | 0.00% | 0.00% |
| 2017 | 0.00% | 0.00% |
Операционная маржа для аналогичных компаний или конкурентов
| Компания | Операционная маржа | Разница в операционной марже | Страна |
|---|---|---|---|
| 38.59% | -100.42% |
US
|
|
| -149.01% | -98.39% |
US
|
|
| 25.57% | -100.28% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.31% |
NL
|
Что такое операционная маржа компании?
Операционная маржа — это ключевой показатель прибыльности компании. Более высокая операционная маржа обычно означает, что компания может продавать свои товары или услуги значительно дороже их себестоимости. Она рассчитывается путем деления прибыли компании на её выручку.